April 2，A high -standard signing ceremony was held in Beijing，Participants include Beijing leaders and China Resources Group (hereinafter referred to as China Resources)。  
    After the signature ceremony，Sources close to China Resources disclosed，The core content of this cooperation，It is China Resources Pharmaceuticals under China Resources Pharmaceuticals holding 100%holding Beijing Pharmaceutical Group (hereinafter referred to as North Medicine)。As a consideration，Beijing to hold 30%of China Resources Pharmaceuticals。China Resources will set the medical headquarters in Beijing。  
    This indicates that after the reorganization of the Chinese medicine is completed，The last step of the "5 in 3" of pharmaceutical central enterprises is finally officially settled。And China Resources Mandarin Holdings Holding North Medicine for nearly four years，Finally, as expected。Bei Pharmaceuticals，China Resources Pharmaceutical will be integrated with the Chinese Medicine Group、Stake Sports BettingMy stake betting appNew medicine forms a three -legged trend。  
    North Medicine is the city of China Resources  
    The connection between China Resources and Bei Pharmaceuticals began in the reorganization of Huayuan。February 16, 2006，China Resources takes over and reorganize Huayuan，In the phase is the 50%of Huayuan's shareholding of Beijing Pharmaceuticals，and 40%of Shanghai Medicine (hereinafter referred to as the medicine)。China Resources hopes to borrow a reorganization to add code to the pharmaceutical platform that is working hard to build。  
    Beida medicine was formerly known as Beijing Medical Factory。September 2004，The company introduced Huayuan，Transformation into a large -scale comprehensive pharmaceutical industry group with a diversified equity。Huayuan at that time to increase the capital of Northern Medicine 988 million yuan，50%equity of North Medicine。50%of the equity of North Medicine，Divided by Beijing State -owned Assets Supervision and Administration Commission、It is held by its Beijing State -owned Assets Supervision and Administration Commission，The share ratio is 20%and 30%each。  
    China Resources Reorganization Huayuan，Always trying to change the pattern of dividing the equity equity of Beijing Pharmaceutical with the Beijing State -owned Assets Supervision Commission。"But the consideration keeps talking about。"" Intellectual revealed。
     At the same time，China Resources and Shanghai State -owned Assets Supervision and Administration Commission also launched negotiations，Hope to hold the medicine。40%of the equity of the medicine belongs to Huayuan，Another 60%of the equity of Shanghai Industrial Investment (Group) Co., Ltd.、Shanghai Huayi (Group) Company equity，The latter two companies are under the jurisdiction of the Shanghai State -owned Assets Supervision and Administration Commission。But the negotiation with Shanghai finally failed，China Resources finally had to withdraw from the medicine。Under the arrangement of the Shanghai SASAC，stake sports betting appstake sports betting appThe medicine reached an agreement with Shanghai Industrial Group (hereinafter referred to as Shangshi Group)，Jointly form a new medicine group。  
    After losing the medicine，Northern Medicine's significance to China Resources is more important。Said the person who knows，"No North Medicine，China Resources Pharmaceutical has no volume，Not enough to build a pharmaceutical platform。”  
    Beida's sales revenue in 2009 26.9 billion yuan，ranking second only to China Pharmaceutical Group Corporation (hereinafter referred to as Chinese Medicine Group)、New Medicine Group，ranked third among Chinese pharmaceutical companies。More than 17,000 employees，Holdings participating in more than 20 companies，It has Shuanghe Pharmaceutical (600062)、Wandong Medical (600055) two listed companies，Another Zizhu Pharmaceutical，Also with natural medicine、Prescription medicine two business departments。In addition，Jurisdiction of Beidao Pharmaceutical Co., Ltd.、Anhui Huayuan、Kunshan Medicine、Four commercial circulation enterprises in New Northwest Shuanghe。  
    Since then，China Resources passed the reorganization of another central enterprise Sanjiu Group，Received pharmaceutical assets such as Sanjiu Pharmaceutical (000999)，But the scale is far less than the northern medicine。Three -nine Pharmaceutical's net profit in 2009 reached 709 million yuan，But operating income is only 4.853 billion yuan。Another Medical Assets East Ejiao (000423)，It is China Resources acquired in December 2004，Currently only 23.14%of the shares，In 2008, sales revenue was 1.686 billion yuan。"If you build a pharmaceutical platform，North Medicine is the city that must be down。"" Kimper said。  
    China Resources Pharmaceutical Super Supreme Medicine is the second child  
    But，Take over Huayuan、After the Three Nine，China Resources is deeply trapped stake online sports bettingstake online sports bettingin reorganized quagmire。At this time，Another pharmaceutical platform for central enterprises ?? Chinese Medicine Group has gradually taken shape，The competition situation is quite grim for China Resources。  
    The National Medicine Group is also an enterprise directly under the State -owned Assets Supervision and Administration Commission of the State Council。September 16, 2009，The State -owned Assets Supervision and Administration Commission of the State Council approves the reorganization of the Chinese Medicine Group and China Biotechnology Group Corporation (hereinafter referred to as Zhongsheng Group)，Zhongsheng Group as a whole merged into the national medicine。Reorganized Chinese Medicine Group，It owns 22 wholly -owned or holding subsidiaries，Holding Chinese Medicine Holdings (01099.HK) and Tiantan Biological (600161)、Chinese Medicine Shares (600511)、Consistent Pharmaceutical (000028) and other three A -share listed companies。In 2009, its operating income was 65 billion yuan，ranked 50th in 129 central enterprises，Total profit ranking 38th。  
    In addition，The National Medicine Group also plans to include the Shanghai Medical Industry Research Institute into the layout，At present, only one paper approval。  
    At the same time，The reorganization of the medicine group is also dazzling。October 2009，Shanghai Pharmaceutical (600849) under the Pharmaceutical Group through absorption and merging、How to issue shares to buy assets，Integrate the pharmaceutical assets of Shangshi Group and Shang Pharmaceutical Group，A new medicine surface surface，Become a unified pharmaceutical industry resource integration platform for the Shanghai SASAC。The annual sales revenue of the new medicine is expected to be around 30 billion yuan，second only to Sinopharm Group，ranked second in Chinese pharmaceutical companies。and China Resources gathered Huayuan、After the pharmaceutical assets of Sanjiu，Its total pharmaceutical assets are about 26 billion yuan，stake betting appMy stake betting appAnnual turnover of more than 27 billion yuan。Holding North Medicine success will help China Resources exceed the new medicine，Enter the second overlap of pharmaceutical companies。  
    Take the northern medicine to smoothly get the northern medicine，China Resources and Beijing have also made some exchange in other respects，For example, increase investment in other aspects of Beijing，China Resources ’s power and micro -electrical company cooperation with Beijing enterprises。